Information Provided By:
Fly News Breaks for April 16, 2019
BDSI
Apr 16, 2019 | 07:13 EDT
Cantor Fitzgerald analyst Brandon Folkes views BioDelivery Sciences' acquisition of Symproic as a positive saying it diversifies the company's revenue away from a single product, Belbuca, and can add a "meaningful "revenue contribution of $75M-plus "without the need for any significant increase in spending." The acquisition is a positive step towards building a "significantly" larger company, focusing on pain, and the complications around pain treatment, Folkes tells investors in a research note. He reiterates an Overweight rating on the shares with an $8 price target.
News For BDSI From the Last 2 Days
There are no results for your query BDSI